Current status for influenza control
Identifieur interne : 000906 ( Istex/Corpus ); précédent : 000905; suivant : 000907Current status for influenza control
Auteurs : Kwang-Hee Lee ; Baik L. SeongSource :
- Biotechnology and Bioprocess Engineering [ 1226-8372 ] ; 1999-10-01.
English descriptors
- KwdEn :
Abstract
Abstract: Influenza viruses are responsible for respiratory illness with significant morbidity and mortality. To curb the disease, two-pronged attack on the virus, therapeutic and prophylactic, is being actively pursued. The therapeutic use of existing anti-influenza drugs, such as amantadine and rimantadine, is limited by their significant adverse side effect, emergence of resistant viral strains, and lack of activity against influenza B virus. A new class of antiviral agents designed to inhibit influenza neuraminidase are currently under active development for use in the prophylaxis and treatment of influenza A and B virus infections. Two of these compounds, zanamivir (GG167) and GS4104 have reached clinical trials. Limitations in the effectiveness and application of inactivated vaccines have stimulated development of alternative approaches to influenza immunization. One such approach is a live, intranasally administered vaccine, attenuated by cold-adaptation of a master strain with subsequent genetic reassortment with circulating wild-type strains. Recently developed reverse-genetics techniques have made it possible to use RNA viruses as vector. Besides DNA viral vectors, live influenza virus vectors may emerge as a useful alternative for the vaccination against different pathogens.
Url:
DOI: 10.1007/BF02931921
Links to Exploration step
ISTEX:556F0EBBCC7AAD3A864B73473DD6B7325C7493BELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current status for influenza control</title><author><name sortKey="Lee, Kwang Hee" sort="Lee, Kwang Hee" uniqKey="Lee K" first="Kwang-Hee" last="Lee">Kwang-Hee Lee</name><affiliation><mods:affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Seong, Baik L" sort="Seong, Baik L" uniqKey="Seong B" first="Baik L." last="Seong">Baik L. Seong</name><affiliation><mods:affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: blseong@bubble.yonsei.ac.kr</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:556F0EBBCC7AAD3A864B73473DD6B7325C7493BE</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1007/BF02931921</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-3NDSG23G-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000906</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000906</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Current status for influenza control</title><author><name sortKey="Lee, Kwang Hee" sort="Lee, Kwang Hee" uniqKey="Lee K" first="Kwang-Hee" last="Lee">Kwang-Hee Lee</name><affiliation><mods:affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Seong, Baik L" sort="Seong, Baik L" uniqKey="Seong B" first="Baik L." last="Seong">Baik L. Seong</name><affiliation><mods:affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: blseong@bubble.yonsei.ac.kr</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Biotechnology and Bioprocess Engineering</title><title level="j" type="abbrev">Biotechnol. Bioprocess Eng.</title><idno type="ISSN">1226-8372</idno><idno type="eISSN">1976-3816</idno><imprint><publisher>The Korean Society for Biotechnology and Bioengineering</publisher><pubPlace>Seoul</pubPlace><date type="published" when="1999-10-01">1999-10-01</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="164">164</biblScope></imprint><idno type="ISSN">1226-8372</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1226-8372</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antiviral drugs</term><term>genetic manipulation</term><term>influenza virus</term><term>reverse genetics</term><term>vaccine</term><term>viral vector</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Influenza viruses are responsible for respiratory illness with significant morbidity and mortality. To curb the disease, two-pronged attack on the virus, therapeutic and prophylactic, is being actively pursued. The therapeutic use of existing anti-influenza drugs, such as amantadine and rimantadine, is limited by their significant adverse side effect, emergence of resistant viral strains, and lack of activity against influenza B virus. A new class of antiviral agents designed to inhibit influenza neuraminidase are currently under active development for use in the prophylaxis and treatment of influenza A and B virus infections. Two of these compounds, zanamivir (GG167) and GS4104 have reached clinical trials. Limitations in the effectiveness and application of inactivated vaccines have stimulated development of alternative approaches to influenza immunization. One such approach is a live, intranasally administered vaccine, attenuated by cold-adaptation of a master strain with subsequent genetic reassortment with circulating wild-type strains. Recently developed reverse-genetics techniques have made it possible to use RNA viruses as vector. Besides DNA viral vectors, live influenza virus vectors may emerge as a useful alternative for the vaccination against different pathogens.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Kwang-Hee Lee</name><affiliations><json:string>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Baik L. Seong</name><affiliations><json:string>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</json:string><json:string>E-mail: blseong@bubble.yonsei.ac.kr</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>influenza virus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vaccine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genetic manipulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>reverse genetics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>viral vector</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antiviral drugs</value></json:item></subject><articleId><json:string>BF02931921</json:string><json:string>Art1</json:string></articleId><arkIstex>ark:/67375/VQC-3NDSG23G-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Influenza viruses are responsible for respiratory illness with significant morbidity and mortality. To curb the disease, two-pronged attack on the virus, therapeutic and prophylactic, is being actively pursued. The therapeutic use of existing anti-influenza drugs, such as amantadine and rimantadine, is limited by their significant adverse side effect, emergence of resistant viral strains, and lack of activity against influenza B virus. A new class of antiviral agents designed to inhibit influenza neuraminidase are currently under active development for use in the prophylaxis and treatment of influenza A and B virus infections. Two of these compounds, zanamivir (GG167) and GS4104 have reached clinical trials. Limitations in the effectiveness and application of inactivated vaccines have stimulated development of alternative approaches to influenza immunization. One such approach is a live, intranasally administered vaccine, attenuated by cold-adaptation of a master strain with subsequent genetic reassortment with circulating wild-type strains. Recently developed reverse-genetics techniques have made it possible to use RNA viruses as vector. Besides DNA viral vectors, live influenza virus vectors may emerge as a useful alternative for the vaccination against different pathogens.</abstract><qualityIndicators><score>9.16</score><pdfWordCount>5420</pdfWordCount><pdfCharCount>33992</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>180</abstractWordCount><abstractCharCount>1306</abstractCharCount><keywordCount>6</keywordCount></qualityIndicators><title>Current status for influenza control</title><genre><json:string>research-article</json:string></genre><host><title>Biotechnology and Bioprocess Engineering</title><language><json:string>unknown</json:string></language><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><issn><json:string>1226-8372</json:string></issn><eissn><json:string>1976-3816</json:string></eissn><journalId><json:string>12257</json:string></journalId><volume>4</volume><issue>3</issue><pages><first>157</first><last>164</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Chemistry</value></json:item><json:item><value>Biotechnology</value></json:item><json:item><value>Industrial and Production Engineering</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-3NDSG23G-J</json:string></ark><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1007/BF02931921</json:string></doi><id>556F0EBBCC7AAD3A864B73473DD6B7325C7493BE</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-3NDSG23G-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-3NDSG23G-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-3NDSG23G-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Current status for influenza control</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">The Korean Society for Biotechnology and Bioengineering</publisher><pubPlace>Seoul</pubPlace><availability><licence><p>The Korean Society for Biotechnology and Bioengineering, 1999</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>1999</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Current status for influenza control</title><author xml:id="author-0000"><persName><forename type="first">Kwang-Hee</forename><surname>Lee</surname></persName><affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</affiliation></author><author xml:id="author-0001" corresp="yes"><persName><forename type="first">Baik</forename><surname>Seong</surname></persName><email>blseong@bubble.yonsei.ac.kr</email><affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</affiliation></author><idno type="istex">556F0EBBCC7AAD3A864B73473DD6B7325C7493BE</idno><idno type="ark">ark:/67375/VQC-3NDSG23G-J</idno><idno type="DOI">10.1007/BF02931921</idno><idno type="article-id">BF02931921</idno><idno type="article-id">Art1</idno></analytic><monogr><title level="j">Biotechnology and Bioprocess Engineering</title><title level="j" type="abbrev">Biotechnol. Bioprocess Eng.</title><idno type="pISSN">1226-8372</idno><idno type="eISSN">1976-3816</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">15</idno><idno type="volume-issue-count">4</idno><imprint><publisher>The Korean Society for Biotechnology and Bioengineering</publisher><pubPlace>Seoul</pubPlace><date type="published" when="1999-10-01"></date><biblScope unit="volume">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="164">164</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Influenza viruses are responsible for respiratory illness with significant morbidity and mortality. To curb the disease, two-pronged attack on the virus, therapeutic and prophylactic, is being actively pursued. The therapeutic use of existing anti-influenza drugs, such as amantadine and rimantadine, is limited by their significant adverse side effect, emergence of resistant viral strains, and lack of activity against influenza B virus. A new class of antiviral agents designed to inhibit influenza neuraminidase are currently under active development for use in the prophylaxis and treatment of influenza A and B virus infections. Two of these compounds, zanamivir (GG167) and GS4104 have reached clinical trials. Limitations in the effectiveness and application of inactivated vaccines have stimulated development of alternative approaches to influenza immunization. One such approach is a live, intranasally administered vaccine, attenuated by cold-adaptation of a master strain with subsequent genetic reassortment with circulating wild-type strains. Recently developed reverse-genetics techniques have made it possible to use RNA viruses as vector. Besides DNA viral vectors, live influenza virus vectors may emerge as a useful alternative for the vaccination against different pathogens.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Key words</head><item><term>influenza virus</term></item><item><term>vaccine</term></item><item><term>genetic manipulation</term></item><item><term>reverse genetics</term></item><item><term>viral vector</term></item><item><term>antiviral drugs</term></item></list></keywords></textClass><textClass><keywords scheme="Journal-Subject-Group"><list><label>C</label><item><term>Chemistry</term></item><label>C12002</label><item><term>Biotechnology</term></item><label>T22008</label><item><term>Industrial and Production Engineering</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-10-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-3NDSG23G-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>The Korean Society for Biotechnology and Bioengineering</PublisherName><PublisherLocation>Seoul</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>12257</JournalID><JournalPrintISSN>1226-8372</JournalPrintISSN><JournalElectronicISSN>1976-3816</JournalElectronicISSN><JournalTitle>Biotechnology and Bioprocess Engineering</JournalTitle><JournalAbbreviatedTitle>Biotechnol. Bioprocess Eng.</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Code="C" Type="Primary">Chemistry</JournalSubject><JournalSubject Code="C12002" Priority="1" Type="Secondary">Biotechnology</JournalSubject><JournalSubject Code="T22008" Priority="2" Type="Secondary">Industrial and Production Engineering</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>4</VolumeIDStart><VolumeIDEnd>4</VolumeIDEnd><VolumeIssueCount>4</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd><IssueArticleCount>15</IssueArticleCount><IssueHistory><CoverDate><Year>1999</Year><Month>10</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>The Korean Society for Biotechnology and Bioengineering</CopyrightHolderName><CopyrightYear>1999</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art1"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>BF02931921</ArticleID><ArticleDOI>10.1007/BF02931921</ArticleDOI><ArticleSequenceNumber>1</ArticleSequenceNumber><ArticleTitle Language="En">Current status for influenza control</ArticleTitle><ArticleFirstPage>157</ArticleFirstPage><ArticleLastPage>164</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2008</Year><Month>7</Month><Day>9</Day></RegistrationDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>The Korean Society for Biotechnology and Bioengineering</CopyrightHolderName><CopyrightYear>1999</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>12257</JournalID><VolumeIDStart>4</VolumeIDStart><VolumeIDEnd>4</VolumeIDEnd><IssueIDStart>3</IssueIDStart><IssueIDEnd>3</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Kwang-Hee</GivenName><FamilyName>Lee</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Baik</GivenName><GivenName>L.</GivenName><FamilyName>Seong</FamilyName></AuthorName><Contact><Phone>+82-2-361-2885</Phone><Fax>+82-2-362-7265</Fax><Email>blseong@bubble.yonsei.ac.kr</Email></Contact></Author><Affiliation ID="Aff1"><OrgDivision>Department of Biotechnology and Bioproducts Research Center, College of Engineering</OrgDivision><OrgName>Yonsei University</OrgName><OrgAddress><Street>134 Shinchon-dong, Seodaemun-gu</Street><Postcode>120-749</Postcode><City>Seoul</City><Country>Korea</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading><Para>Influenza viruses are responsible for respiratory illness with significant morbidity and mortality. To curb the disease, two-pronged attack on the virus, therapeutic and prophylactic, is being actively pursued. The therapeutic use of existing anti-influenza drugs, such as amantadine and rimantadine, is limited by their significant adverse side effect, emergence of resistant viral strains, and lack of activity against influenza B virus. A new class of antiviral agents designed to inhibit influenza neuraminidase are currently under active development for use in the prophylaxis and treatment of influenza A and B virus infections. Two of these compounds, zanamivir (GG167) and GS4104 have reached clinical trials. Limitations in the effectiveness and application of inactivated vaccines have stimulated development of alternative approaches to influenza immunization. One such approach is a live, intranasally administered vaccine, attenuated by cold-adaptation of a master strain with subsequent genetic reassortment with circulating wild-type strains. Recently developed reverse-genetics techniques have made it possible to use RNA viruses as vector. Besides DNA viral vectors, live influenza virus vectors may emerge as a useful alternative for the vaccination against different pathogens.</Para></Abstract><KeywordGroup Language="En"><Heading>Key words</Heading><Keyword>influenza virus</Keyword><Keyword>vaccine</Keyword><Keyword>genetic manipulation</Keyword><Keyword>reverse genetics</Keyword><Keyword>viral vector</Keyword><Keyword>antiviral drugs</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Current status for influenza control</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Current status for influenza control</title></titleInfo><name type="personal"><namePart type="given">Kwang-Hee</namePart><namePart type="family">Lee</namePart><affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">Baik</namePart><namePart type="given">L.</namePart><namePart type="family">Seong</namePart><affiliation>Department of Biotechnology and Bioproducts Research Center, College of Engineering, Yonsei University, 134 Shinchon-dong, Seodaemun-gu, 120-749, Seoul, Korea</affiliation><affiliation>E-mail: blseong@bubble.yonsei.ac.kr</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The Korean Society for Biotechnology and Bioengineering</publisher><place><placeTerm type="text">Seoul</placeTerm></place><dateIssued encoding="w3cdtf">1999-10-01</dateIssued><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Influenza viruses are responsible for respiratory illness with significant morbidity and mortality. To curb the disease, two-pronged attack on the virus, therapeutic and prophylactic, is being actively pursued. The therapeutic use of existing anti-influenza drugs, such as amantadine and rimantadine, is limited by their significant adverse side effect, emergence of resistant viral strains, and lack of activity against influenza B virus. A new class of antiviral agents designed to inhibit influenza neuraminidase are currently under active development for use in the prophylaxis and treatment of influenza A and B virus infections. Two of these compounds, zanamivir (GG167) and GS4104 have reached clinical trials. Limitations in the effectiveness and application of inactivated vaccines have stimulated development of alternative approaches to influenza immunization. One such approach is a live, intranasally administered vaccine, attenuated by cold-adaptation of a master strain with subsequent genetic reassortment with circulating wild-type strains. Recently developed reverse-genetics techniques have made it possible to use RNA viruses as vector. Besides DNA viral vectors, live influenza virus vectors may emerge as a useful alternative for the vaccination against different pathogens.</abstract><subject lang="en"><genre>Key words</genre><topic>influenza virus</topic><topic>vaccine</topic><topic>genetic manipulation</topic><topic>reverse genetics</topic><topic>viral vector</topic><topic>antiviral drugs</topic></subject><relatedItem type="host"><titleInfo><title>Biotechnology and Bioprocess Engineering</title></titleInfo><titleInfo type="abbreviated"><title>Biotechnol. Bioprocess Eng.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">1999-10-01</dateIssued><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><subject><genre>Journal-Subject-Group</genre><topic authority="SpringerSubjectCodes" authorityURI="C">Chemistry</topic><topic authority="SpringerSubjectCodes" authorityURI="C12002">Biotechnology</topic><topic authority="SpringerSubjectCodes" authorityURI="T22008">Industrial and Production Engineering</topic></subject><identifier type="ISSN">1226-8372</identifier><identifier type="eISSN">1976-3816</identifier><identifier type="JournalID">12257</identifier><identifier type="IssueArticleCount">15</identifier><identifier type="VolumeIssueCount">4</identifier><part><date>1999</date><detail type="volume"><number>4</number><caption>vol.</caption></detail><detail type="issue"><number>3</number><caption>no.</caption></detail><extent unit="pages"><start>157</start><end>164</end></extent></part><recordInfo><recordOrigin>The Korean Society for Biotechnology and Bioengineering, 1999</recordOrigin></recordInfo></relatedItem><identifier type="istex">556F0EBBCC7AAD3A864B73473DD6B7325C7493BE</identifier><identifier type="ark">ark:/67375/VQC-3NDSG23G-J</identifier><identifier type="DOI">10.1007/BF02931921</identifier><identifier type="ArticleID">BF02931921</identifier><identifier type="ArticleID">Art1</identifier><accessCondition type="use and reproduction" contentType="copyright">The Korean Society for Biotechnology and Bioengineering, 1999</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>The Korean Society for Biotechnology and Bioengineering, 1999</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-3NDSG23G-J/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000906 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000906 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:556F0EBBCC7AAD3A864B73473DD6B7325C7493BE
|texte= Current status for influenza control
}}
| This area was generated with Dilib version V0.6.33. |  |